ateapharma.com - AVIR Net Assets per Single Share

Atea Pharmaceuticals (AVIR) specializes in developing oral antivirals, effectively collaborating with pharma behemoths to bring products to market. The linear price action on the GURU.Markets chart reaches 2.53. Growth is accelerating through the implementation of AI models and robotics for formula selection, while research stability is guaranteed by a sophisticated international supply system for biochemical raw materials.

Atea Pharma (AVIR): Share Book Value from 07/04/2022 to 10/27/2026

ateapharma.com - analytical breakdowns and key metrics (AVIR)

- price and consensus price forecast:

Stock Price Atea Pharmaceuticals Inc|AVIR - Analyst Median Target

- market capitalization data:

Market Value Atea Pharmaceuticals, Inc.|AVIR - Value Adjusted for Debt and Cash

- book capitalization data:

Net Assets per Single Share Atea Pharmaceuticals|AVIR - Net Asset Value|Market Capitalization to Book Value Ratio ateapharma.com|AVIR - Aggregate Asset Value

- debt and liquidity data:

Total Debt to Capital Atea Pharmaceuticals|AVIR - Long-Term Debt to Capital|Short-Term Debt to Equity Atea Pharmaceuticals, Inc.|AVIR - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Atea Pharmaceuticals, Inc.

Fundamental company valuation:Atea Pharmaceuticals Inc - AVIR

Manufactured products of Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals (AVIR) minimizes capital expenditures by outsourcing production and clinical trials to third-party contractors, which directly impacts its asset structure. The trend in book value per common share reflects the remaining equity per share after deducting all liabilities, allowing investors to assess the real value of assets and promptly identify hidden write-downs or equity dilution.

Competitors of Atea Pharmaceuticals (AVIR)

Book Value per Share GILD (Gilead Sciences Inc)|CDTX: Net Assets per Share|Net Assets per Single Share Novavax, Inc. NVAX|CVAC (curevac.com) - Accounting Value of a Share|Net Assets per Single Share Valneva VALN|Share Book Value Vir Biotechnology Inc|SIGA Corp (SIGA) - Book Value per Share|Accounting Value of a Share Emergent Bio (EBS)|Book Value per Share IVVD (Invivyd)|enanta.com - Book Value per Share|Net Assets per Single Share Inovio (INO)|HLVX: Accounting Value of a Share|KLRS (Kalaris Therapeutics, Inc.) - Net Assets per Single Share|Dyadic International, Inc. (DYAI) - Accounting Value per Share|NNVC (NanoViricides Inc.) - Book Value per Share|Book Value per Share talphera.com (TLPH)|Cocrystal Pharma (COCP) - Accounting Value per Share|Accounting Value of a Share trawspharma.com TRAW|Accounting Value per Share Dogwood Therapeutics DWTX|Net Assets per Single Share Qualigen Corp QLGN|Book Value per Share ALVR (AlloVir Bio)|VBIV: Net Assets per Share|Net Assets per Single Share virios.com VIRI|Accounting Value of a Share Vaxart